Claudin-low breast cancers share features with TNBC including frequent loss of ER, PR and HER2 expression, high expression of mesenchymal genes and features of an epithelial–mesenchymal transition (EMT) phenotype [35]. This evidence concerns the gene ERBB2 and breast cancer.